心血管-脏-代谢作用:类固醇和非类固醇矿物质皮质类受体对手
Biykem Bozkurt1, James L Januzzi2,3, Shweta Bansal4
1Winters Center for Heart Failure Research, Cardiovascular Research Institute, Baylor College of Medicine, Houston, TX 77030, USA.
Reviews in cardiovascular medicine
|August 8, 2025
概括
矿物质皮质类受体抗剂 (MRAs) 在治疗心血管--代谢 (CKM) 综合征方面表现有前途. 类固醇和非类固醇MRA在CKM患者的心力衰竭,慢性病和高血压方面都有好处.
科学领域:
- 内分泌学和新陈代谢学
- 心脏病学 心脏病学
- 腎臟病學 (nephrology) 是一種醫學專業.
背景情况:
- 心血管--代谢 (CKM) 综合征涉及诸如慢性病 (CKD),高血压和代谢功能障碍等相互关联的风险.
- 过度活跃的矿物质皮质体受体信号传递有助于CKM的发病.
- 目前的治疗方法包括类固醇矿物质皮质体受体对抗剂 (MRA).
研究的目的:
- 审查用于管理CKM综合征的矿物质皮质类受体抗剂 (MRA) 的临床证据.
- 讨论非类固醇MRA在CKM中的演变作用.
- 突出MRA在各种心血管和脏疾病中的有效性.
主要方法:
- 对CKM综合征中MRA使用的当前临床证据的审查.
- 对类固醇和非类固醇MRA的临床试验数据的分析.
- 检查MRA在心力衰竭,CKD和高血压中的疗效.
主要成果:
- 类固醇MRA对心力衰竭有减少喷射率,高血压和CKD有效.
- 非类固醇MRAfinerenone在特定患者群体中减少CV和CKD进展.
- 目前正在进行的试验正在更广泛的心力衰竭人群中探索非类固醇MRA.
结论:
- 矿物质皮质类受体抗剂 (MRAs) 在管理CKM综合征方面至关重要.
- 非类固醇MRA代表了对CKM的有希望的治疗途径.
- 进一步的研究可能会扩大CKM中的MRA应用.
相关概念视频
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
509
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
509
01:27Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers
981
β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in...
981
01:17Antihypertensive Drugs: Action of β1 Blockers
612
β1-receptors are primarily located in the heart and kidneys. In cardiac myocytes, these receptors interact with neurotransmitters released by the sympathetic nervous system during heightened activity or danger. As a result, β1-receptors get activated, initiating a series of biochemical processes. Excessive activation of beta receptors due to chronic stress can abnormally increase heart rate and contractility, resulting in high blood pressure or hypertension. To counteract this,...
612
01:28Antihypertensive Drugs: Potassium-Sparing Diuretics
769
Liddle syndrome is a genetically inherited form of hypertension characterized by the overactivity of epithelial sodium channels in the nephron, the functional unit of the kidney. This heightened activity leads to increased sodium reabsorption and excessive excretion of potassium. To counteract this, potassium-sparing diuretics such as amiloride are used. They function by blocking these sodium channels, thereby reducing the influx of sodium into the epithelial cells and minimizing the loss of...
769
01:22Heart Failure Drugs: Diuretics
486
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
486
01:30Antihypertensive Drugs: Angiotensin II Receptor Blockers
925
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
925